Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer

Immunotherapy has significantly changed the treatment landscape for advanced non-small-cell lung cancer (NSCLC) with the introduction of drugs targeting programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1). In particular, the addition of the anti-PD-1 antibody pembrolizu...

Full description

Bibliographic Details
Main Authors: Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, Silvia La Monica, Claudia Fumarola, Maricla Galetti, Mara Bonelli, Daniele Cretella, Valeria Barili, Alessandra Zecca, Elisa Giovannetti, Michelangelo Fiorentino, Marcello Tiseo, Pier Giorgio Petronini, Andrea Ardizzoni
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
pemetrexed
pd-l1
ifn-γ
nsclc
chemotherapy
Online Access:https://www.mdpi.com/2072-6694/12/3/666

Similar Items

Similar Items